Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
17.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
17.06. | PolyPid stock price target lowered to $14 at JMP on warrant dilution | 2 | Investing.com | ||
17.06. | PolyPid Ltd.: PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results | 1 | GlobeNewswire (USA) | ||
10.06. | PolyPid reports positive phase 3 surgical infection drug trial | 2 | Globes | ||
09.06. | Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial | 1 | Benzinga.com | ||
09.06. | PolyPid shares surge on successful D-PLEX100 trial results | 1 | Investing.com | ||
POLYPID Aktie jetzt für 0€ handeln | |||||
09.06. | PolyPid Ltd.: PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX100 Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints | 213 | GlobeNewswire (Europe) | D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (pThe trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the... ► Artikel lesen | |
09.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
02.06. | H.C. Wainwright nimmt Beobachtung der PolyPid-Aktie mit Kaufempfehlung auf | 3 | Investing.com Deutsch | ||
30.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
29.05. | PolyPid bei Lytham Partners: Strategische Fortschritte und finanzielle Stabilität | 3 | Investing.com Deutsch | ||
21.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
14.05. | PolyPid GAAP EPS of -$0.70 beats by $0.12 | 1 | Seeking Alpha | ||
14.05. | PolyPid Ltd. Q1 Loss Beats Estimates | - | RTTNews | ||
14.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
13.05. | A Look Ahead: PolyPid's Earnings Forecast | 1 | Benzinga.com | ||
29.04. | PolyPid Ltd.: PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 | 2 | GlobeNewswire (USA) | ||
14.04. | H.C. Wainwright maintains Buy on PolyPid stock with $11 target | 2 | Investing.com | ||
11.03. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Evotec steigt in Mega-Forschungsprojekt ein - Hoffnungsschimmer für Millionen Nierenpatienten | Evotec SE treibt seine Strategie in der personalisierten Medizin weiter voran und verkündet den Beitritt zum renommierten NURTuRE-AKI-Konsortium. Mit diesem Schritt zielt das MDAX- und TecDAX-notierte... ► Artikel lesen | |
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
AMGEN | 237,00 | +0,11 % | Amgen-Aktie mit Kursverlusten (237,1233 €) | An der US-amerikanischen Börse notiert die Aktie von Amgen derzeit etwas leichter. Der jüngste Kurs betrug 277,19 US-Dollar. An der Börse liegt die Aktie von Amgen zur Stunde im Minus. Das Wertpapier... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,450 | +2,27 % | Biotech-Pick: Warum sie diese Aktie unbedingt auf dem Zettel haben sollten! | ||
IBIO | 0,745 | +4,93 % | Pharos iBio Receives IND Approval for PHI-501 Phase 1 Trial | ||
ARROWHEAD PHARMACEUTICALS | 13,400 | -2,40 % | Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results | PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting... ► Artikel lesen | |
COHERUS ONCOLOGY | 0,643 | +1,42 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
VOYAGER THERAPEUTICS | 2,494 | -1,27 % | Voyager Therapeutics, Inc.: Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced... ► Artikel lesen | |
OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report | ||
MEREO BIOPHARMA | 2,330 | +2,19 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights | Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE... ► Artikel lesen | |
APELLIS PHARMACEUTICALS | 15,634 | +5,08 % | Swedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases | STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating... ► Artikel lesen | |
BENITEC BIOPHARMA | 11,260 | -8,83 % | Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update | -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular... ► Artikel lesen | |
CYBIN | 7,100 | +0,71 % | Neural Therapeutics: Innovative Meskalin-Therapien für psychische Gesundheit |